Focus: SetPoint Medical is a public biotech company specializing in bioelectric medicine, focusing on neuroimmune modulation via vagus nerve stimulation for immunology and neurology indications. The company operates at early-to-mid stage development with a lean footprint.
Profile data last refreshed 10h ago · AI intelligence enriched 3w ago
Growing — net +18 jobs in 30d
21 jobs added vs 3 removed. Steady team buildout.
Suitable for scientists/engineers committed to pioneering neuromodulation science in early-stage settings; poor fit for those seeking rapid career progression or established company stability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for SetPoint Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from SetPoint Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
SetPoint Medical Announces Publication of Cost-Effectiveness Study Confirming Neuroimmune Modulation Can Reduce Total Cost of Care and Improve Quality of Life for Patients with Rheumatoid Arthritis - PR Newswire
SetPoint Medical Announces Publication of Cost-Effectiveness Study Confirming Neuroimmune Modulation Can Reduce Total Cost of Care and Improve Quality of Life for Patients with Rheumatoid Arthritis PR Newswire
SetPoint Medical Announces Publication of Cost-Effectiveness Study Confirming Neuroimmune Modulation Can Reduce Total Cost of Care and Improve Quality of Life for Patients with Rheumatoid Arthritis - BioSpace
SetPoint Medical Announces Publication of Cost-Effectiveness Study Confirming Neuroimmune Modulation Can Reduce Total Cost of Care and Improve Quality of Life for Patients with Rheumatoid Arthritis BioSpace
SetPoint Medical launches first-in-human MS pilot study using implanted nerve stimulation device - Indian Pharma Post
SetPoint Medical launches first-in-human MS pilot study using implanted nerve stimulation device Indian Pharma Post
SetPoint Medical to Participate at the Bank of America Health Care Conference - PR Newswire
SetPoint Medical to Participate at the Bank of America Health Care Conference PR Newswire
SetPoint Medical Announces First Patients Enrolled in Pilot Study Evaluating Neuroimmune Modulation for Multiple Sclerosis - PR Newswire
SetPoint Medical Announces First Patients Enrolled in Pilot Study Evaluating Neuroimmune Modulation for Multiple Sclerosis PR Newswire
SetPoint Medical Announces First Patients Enrolled in Pilot Study Evaluating Neuroimmune Modulation for Multiple Sclerosis - BioSpace
SetPoint Medical Announces First Patients Enrolled in Pilot Study Evaluating Neuroimmune Modulation for Multiple Sclerosis BioSpace
Showing 6 of 8 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo